daunorubicin - CISMeF

Preferred Label : daunorubicin;

MeSH definition : A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.;

MeSH synonym : dauno rubidomycine; rubomycin; daunomycin; rubidomycin; dauno-rubidomycine;

MeSH hyponym : NSC-82151; cerubidine; daunoblastin; daunorubicin hydrochloride; Daunoblastine; NSC 82151; NSC82151; Hydrochloride, Daunorubicin;

MeSH CAS label : 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-;

MeSH Related Number : daunorubicin hydrochloride; 20830-81-3 (Daunorubicin); 23541-50-6 (Daunorubicin hydrochloride); UD984I04LZ;

Registry Number MeSH : 20830-81-3;

Related CAS MeSH : UD984I04LZ (Daunorubicin hydrochloride);

Wikipedia link : https://en.wikipedia.org/wiki/Daunorubicin;

Codes EINECS : 244-069-7;

Is substance : O;

UNII : ZS7284E0ZP;

InChIKey : STQGQHZAVUOBTE-VGBVRHCVSA-N;

Details

Origin ID

D003630;

UMLS CUI

C0011015;

ATC code(s)
- cytarabine and daunorubicin [ATC Code]
- daunorubicin [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Daunorubicin Hydrochloride [NCIt concept]
- Daunorubicin hydrochloride [Substance BNPC]
- Daunorubicin hydrochloride (substance) [SNOMED CT concept]
- Duborimycin [NCIt concept]
- daunorubicin hydrochloride [SNOMED Notion]
CISMeF manual mappings
- daunorubicin [Substance BNPC]
Currated CISMeF NLP mapping
- Daunorubicin [ICD-11 Extension code]
- Daunorubicin [ICHI extension code]
- Daunorubicin [SMS substance]
- Daunorubicin [NCIt concept]
- Daunorubicin (substance) [SNOMED CT concept]
- daunorubicin [SNOMED Notion]
Indexing information
- DrrA protein, streptomyces peucetius [MeSH Supplementary Concept]
- daunorubicin receptor [MeSH Supplementary Concept]
- daunorubicin-binding protein, rat [MeSH Supplementary Concept]
Pharmacological action(s)
- antibiotics, antineoplastic [MeSH Descriptor]
- enzyme inhibitors [MeSH Descriptor]
- topoisomerase II inhibitors [MeSH Descriptor]
Record concept(s)
- NSC-82151 [MeSH concept]
- cerubidine [MeSH concept]
- daunoblastin [MeSH concept]
- daunorubicin [MeSH concept]
- daunorubicin hydrochloride [MeSH concept]
Related MeSH Supplementary Concept(s)
- ((N-morpholine)metylene)daunorubicin [MeSH Supplementary Concept]
- ((N-piperidine)methylene)daunorubicin hydrochloride [MeSH Supplementary Concept]
- ((N-pyrrolidine)methylene)daunorubicin hydrochloride [MeSH Supplementary Concept]
- 06-Paris-LA-66 protocol [MeSH Supplementary Concept]
- 1-hydroxy-13-dihydrodaunomycin [MeSH Supplementary Concept]
- 11-deoxydaunomycin [MeSH Supplementary Concept]
- 11mer daunomycin-conjugated GT [MeSH Supplementary Concept]
- 13-methyl-13-dihydrodaunorubicin [MeSH Supplementary Concept]
- 14-bromodaunorubicin [MeSH Supplementary Concept]
- 14-chlorodaunorubicin [MeSH Supplementary Concept]
- 14-quinaldinoyloxydaunorubicin [MeSH Supplementary Concept]
- 14-salicyloyldaunorubicin [MeSH Supplementary Concept]
- 2'-C-methyldaunomycin [MeSH Supplementary Concept]
- 2-fluoro-4-demethoxydaunomycin [MeSH Supplementary Concept]
- 3',6'-dihydroxy-3',5'-diepidaunorubicin [MeSH Supplementary Concept]
- 3'-(4-methoxy-1-piperidinyl)-3'-deaminodaunorubicin [MeSH Supplementary Concept]
- 3'-(4-morpholinyl)-3'-deaminodaunorubicin [MeSH Supplementary Concept]
- 3'-C-methyldaunorubicin [MeSH Supplementary Concept]
- 3'-azido-3'-deamino daunorubicin [MeSH Supplementary Concept]
- 3'-azido-daunorubicin thiosemicarbazone [MeSH Supplementary Concept]
- 3'-azidodaunorubicin [MeSH Supplementary Concept]
- 3'-deamino-3'-hydroxydaunorubicin [MeSH Supplementary Concept]
- 3'-desamino-3'-dimethylformamidine rubomycin [MeSH Supplementary Concept]
- 3'-epidaunorubicin [MeSH Supplementary Concept]
- 3'-hydroxy-3',5'-diepidaunorubicin [MeSH Supplementary Concept]
- 3-fluoro-4-demethoxydaunomycin [MeSH Supplementary Concept]
- 4 O-daunosaminyl-2,4,5,12-tetrahydroxy-2-nonanoyl-1,2,3,4-tetrahydro-6,11-naphthacenedione [MeSH Supplementary Concept]
- 4'-O-(a-l-cladinosyl)daunorubicin [MeSH Supplementary Concept]
- 4'-O-(oleandrosyl)daunorubicin [MeSH Supplementary Concept]
- 4'-deoxydaunomycin [MeSH Supplementary Concept]
- 4'-epidaunomycin [MeSH Supplementary Concept]
- 4(O)-daunosaminyl-2,4,5,12-tetrahydroxy-2-pentanoyl-1,2,3,4-tetrahydro-6,11-naphthacenedione [MeSH Supplementary Concept]
- 4-O-daunosaminyl-2,4,5,12-tetrahydroxy-2-(2-methylpropanoyl)-1,2,3,4-tetrahydro-6,11-naphthacenedione [MeSH Supplementary Concept]
- 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulfonyldaunorubicin [MeSH Supplementary Concept]
- 4-demethoxy-3'-deamino-4'-deoxy-4'-aminodaunorubicin [MeSH Supplementary Concept]
- 4-methoxydaunorubicin [MeSH Supplementary Concept]
- 5-aminodaunorubicin [MeSH Supplementary Concept]
- 5-imino-N-(1-carboethoxypropen-1-yl)daunorubicin [MeSH Supplementary Concept]
- 5-iminodaunorubicin [MeSH Supplementary Concept]
- 7(O)-(2,3,5-trideoxy-3-C-formylpentafuranosyl)daunomycinone [MeSH Supplementary Concept]
- 7+3 protocol [MeSH Supplementary Concept]
- 7-(3-amino-4-O-(mycarosyl)-2,3,6-trideoxyhexopyranosyl)daunorubicinone [MeSH Supplementary Concept]
- 7-O-(2,6-dideoxy-2-fluoro-4-O-(3-fluorotetrahydropyran-2-yl)talopyranosyl)daunomycinone [MeSH Supplementary Concept]
- 7-O-(2,6-dideoxy-2-fluoro-5-C-(trifluoromethyl)talopyranosyl)daunomycinone [MeSH Supplementary Concept]
- 7-O-(2,6-dideoxy-2-fluorotalopyranosyl)daunomycinone [MeSH Supplementary Concept]
- 7-O-(3-amino-2,3,6-trideoxy-2-fluorotalopyranosyl)daunomycinone [MeSH Supplementary Concept]
- 7-O-(3-amino-2,3,6-trideoxy-6,6,6-trifluoro-lyxo-hexopyranosyl)daunomycinone [MeSH Supplementary Concept]
- 7-O-(3-amino-2,3,6-trideoxy-alpha-ribo-hexopyranosyl)daunomycinone [MeSH Supplementary Concept]
- 7-O-(3-chloro-2,3,6-trideoxy-4-O-propanoyl-lyxo-hexopyranosyl)daunomycinone [MeSH Supplementary Concept]
- 7-O-(4-O-acetyl-3-iodo-2,3,6-trideoxy-arabino-hexopyranosyl)daunomycinone [MeSH Supplementary Concept]
- 7-O-(6-deoxy-2-O-methyltalopyranosyl)daunomycinone [MeSH Supplementary Concept]
- 7-O-ribofuranosyldaunomycinone [MeSH Supplementary Concept]
- 7-deoxy-13-dihydrodaunomycinone [MeSH Supplementary Concept]
- 7-deoxydaunomycinone [MeSH Supplementary Concept]
- 9,10-anhydrodaunorubicin [MeSH Supplementary Concept]
- 9-dehydroxydaunomycin [MeSH Supplementary Concept]
- ABCDV protocol [MeSH Supplementary Concept]
- ADA protocol [MeSH Supplementary Concept]
- AIEOP 8703 protocol [MeSH Supplementary Concept]
- AIEOP acute lymphoblastic leukemia protocol [MeSH Supplementary Concept]
- AIEOP protocol 8202 [MeSH Supplementary Concept]
- AL851 protocol [MeSH Supplementary Concept]
- ALHR88 protocol [MeSH Supplementary Concept]
- ALL-BFM-95 protocol [MeSH Supplementary Concept]
- AML8A protocol [MeSH Supplementary Concept]
- AML91 protocol [MeSH Supplementary Concept]
- AML92 protocol [MeSH Supplementary Concept]
- B-DOMP protocol [MeSH Supplementary Concept]
- BF-9 protocol [MeSH Supplementary Concept]
- BH-AC-DMP protocol [MeSH Supplementary Concept]
- BHAC-DMPV protocol [MeSH Supplementary Concept]
- CART protocol [MeSH Supplementary Concept]
- CDOP protocol [MeSH Supplementary Concept]
- CPX-351 [MeSH Supplementary Concept]
- CROP protocol [MeSH Supplementary Concept]
- D(A)AT protocol [MeSH Supplementary Concept]
- D-ZAPO protocol [MeSH Supplementary Concept]
- DAEP protocol [MeSH Supplementary Concept]
- DAP protocol [MeSH Supplementary Concept]
- DAT protocol 1 [MeSH Supplementary Concept]
- DAT-COAP regimen [MeSH Supplementary Concept]
- DATOP protocol [MeSH Supplementary Concept]
- DATV regimen [MeSH Supplementary Concept]
- DAUFhex compound [MeSH Supplementary Concept]
- DAUFmor compound [MeSH Supplementary Concept]
- DAV regimen [MeSH Supplementary Concept]
- DBVCy protocol [MeSH Supplementary Concept]
- DC(M)VP protocol [MeSH Supplementary Concept]
- DCMP protocol [MeSH Supplementary Concept]
- DCTER protocol [MeSH Supplementary Concept]
- DCTP regimen [MeSH Supplementary Concept]
- DCVP-1-asp protocol [MeSH Supplementary Concept]
- DOA protocol [MeSH Supplementary Concept]
- DOAPP protocol [MeSH Supplementary Concept]
- DON protocol [MeSH Supplementary Concept]
- DVP (daunomycin) [MeSH Supplementary Concept]
- EORTC GIMEMA AML-10 protocol [MeSH Supplementary Concept]
- GAP-POMP regimen [MeSH Supplementary Concept]
- GnRH-III, acetyllysyl(4)-(daunorubicin-aminooxyacetyl)lysyl(8)- [MeSH Supplementary Concept]
- HAD protocol [MeSH Supplementary Concept]
- HDAC protocol [MeSH Supplementary Concept]
- HR-2 protocol [MeSH Supplementary Concept]
- L-6 protocol [MeSH Supplementary Concept]
- LALA 87 protocol [MeSH Supplementary Concept]
- LSA2-L2 protocol [MeSH Supplementary Concept]
- M-DOMP protocol [MeSH Supplementary Concept]
- MAR 70 [MeSH Supplementary Concept]
- MRC AML 10 protocol [MeSH Supplementary Concept]
- MSH-daunomycin conjugate [MeSH Supplementary Concept]
- MSK-NY-II protocol, modified [MeSH Supplementary Concept]
- N,N-dibenzyldaunorubicin [MeSH Supplementary Concept]
- N,N-dimethyldaunorubicin [MeSH Supplementary Concept]
- N-(1-carboethoxylpropen-1-y-2)daunorubicin [MeSH Supplementary Concept]
- N-(4''-(galactopyranosyl)-3''-nitrobenzyloxycarbonyl)daunomycin [MeSH Supplementary Concept]
- N-(4-(daunorubicin-N-carbonyl-oxymethyl)phenyl)-O-glucuronyl carbamate [MeSH Supplementary Concept]
- N-(p-azidobenzoyl)daunorubicin [MeSH Supplementary Concept]
- N-acetyl-13-dihydrodaunomycin [MeSH Supplementary Concept]
- N-acetyldaunomycin [MeSH Supplementary Concept]
- N-aconityldaunomycin [MeSH Supplementary Concept]
- N-butyryldaunorubicin [MeSH Supplementary Concept]
- N-cyanomethyl-N-(2-methoxyethyl)daunomycin [MeSH Supplementary Concept]
- N-ethyl-13-dihydrorubomycin [MeSH Supplementary Concept]
- N-formyl-1-hydroxy-13-dihydrodaunomycin [MeSH Supplementary Concept]
- N-leucyldaunorubicin [MeSH Supplementary Concept]
- N-maleyldaunomycin [MeSH Supplementary Concept]
- N-octanoyldaunorubicin [MeSH Supplementary Concept]
- N-oleyl-daunorubicin [MeSH Supplementary Concept]
- N-palmitoyldaunorubicin [MeSH Supplementary Concept]
- NSC 284682 [MeSH Supplementary Concept]
- NSC 331962 [MeSH Supplementary Concept]
- PETHEMA ALL-96 protocol [MeSH Supplementary Concept]
- PNU 169884 [MeSH Supplementary Concept]
- POG-8498 protocol [MeSH Supplementary Concept]
- PVDA protocol [MeSH Supplementary Concept]
- RACOP protocol [MeSH Supplementary Concept]
- RAP protocol [MeSH Supplementary Concept]
- RATE protocol [MeSH Supplementary Concept]
- ROAP protocol [MeSH Supplementary Concept]
- TRAMPCO protocol [MeSH Supplementary Concept]
- TRAMPCOL protocol [MeSH Supplementary Concept]
- UKALL X protocol [MeSH Supplementary Concept]
- VCRP protocol [MeSH Supplementary Concept]
- VDP protocol [MeSH Supplementary Concept]
- WP 400 [MeSH Supplementary Concept]
- WP 631 [MeSH Supplementary Concept]
- WP 652 [MeSH Supplementary Concept]
- WP 762 [MeSH Supplementary Concept]
- alanylleucyl-daunorubicin [MeSH Supplementary Concept]
- anti-alpha-fetoprotein antibody-daunomycin conjugate [MeSH Supplementary Concept]
- baumycins [MeSH Supplementary Concept]
- bis(14-thiadaunomycin) [MeSH Supplementary Concept]
- bisdaunomycin [MeSH Supplementary Concept]
- cyanomorpholinodaunomycin [MeSH Supplementary Concept]
- daunoform [MeSH Supplementary Concept]
- daunomycin semiquinone [MeSH Supplementary Concept]
- daunomycin-N-(2-hydroxypropyl)methacrylamide copolymer conjugate [MeSH Supplementary Concept]
- daunomycin-albumin conjugate [MeSH Supplementary Concept]
- daunomycin-arachidonic acid complex [MeSH Supplementary Concept]
- daunomycin-dextran [MeSH Supplementary Concept]
- daunomycin-ferretin conjugate [MeSH Supplementary Concept]
- daunophilin [MeSH Supplementary Concept]
- daunorubicin 13-tert-butoxycarbonylhydrazone [MeSH Supplementary Concept]
- daunorubicin polyaspartic acid [MeSH Supplementary Concept]
- daunorubicin semiquinone radicals [MeSH Supplementary Concept]
- daunorubicin-DNA [MeSH Supplementary Concept]
- daunorubicinol [MeSH Supplementary Concept]
- detorubicin [MeSH Supplementary Concept]
- emoxyl [MeSH Supplementary Concept]
- feudomycin A [MeSH Supplementary Concept]
- feudomycin B [MeSH Supplementary Concept]
- feudomycin D [MeSH Supplementary Concept]
- feudomycinone C [MeSH Supplementary Concept]
- idarubicinol [MeSH Supplementary Concept]
- iodomycin [MeSH Supplementary Concept]
- leukaemomycins [MeSH Supplementary Concept]
- moflomycin [MeSH Supplementary Concept]
- new york protocol [MeSH Supplementary Concept]
- non-Hodgkin's lymphoma protocol 8503 [MeSH Supplementary Concept]
- oxazolinodaunorubicin [MeSH Supplementary Concept]
- prolactin-daunomycin ligand [MeSH Supplementary Concept]
- rubomycin 13-cyclohexylidenehydrazone [MeSH Supplementary Concept]
- rubomycin F [MeSH Supplementary Concept]
- rubomycin H [MeSH Supplementary Concept]
- ruboxyl [MeSH Supplementary Concept]
- thyrotropin-alpha-lactalbumin-daunomycin conjugate [MeSH Supplementary Concept]
- thyrotropin-daunomycin conjugate [MeSH Supplementary Concept]
- trifluoroacetyldaunomycin [MeSH Supplementary Concept]
- zorubicin [MeSH Supplementary Concept]
Semantic type(s)
- Antibiotic [UMLS semantic type]
- Organic Chemical [UMLS semantic type]
UMLS correspondences (same concept)
- Daunorubicin [ICD-11 Extension code]
- Daunorubicin [NCIt concept]
- Daunorubicin (substance) [SNOMED CT concept]
- Product containing daunorubicin (medicinal product) [SNOMED CT concept]
- daunorubicin [ATC Code]
- daunorubicin [Substance BNPC]
- daunorubicin [SNOMED Notion]
Validated automatic mappings to BTNT
- Daunorubicin Hydrochloride [NCIt concept]
- Daunorubicin hydrochloride [Substance BNPC]
- Daunorubicin hydrochloride [SMS substance]
- Daunorubicin hydrochloride (substance) [SNOMED CT concept]
- daunorubicin [ATC Code]
- daunorubicin hydrochloride [SNOMED Notion]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients